Home Clinical Topics Medications

Medications

Survey reveals 40% of patients with MS stop taking medications because of cost

A new survey conducted by the National MS Society (NMSS) reveals that 40% of respondents “altered or stopped taking their medication” due to the medication(s) high costs. NMSS also highlights that in 2019, the...

First FDA approved treatment for thyroid eye disease

The U.S. Food and Drug Administration (FDA) recently approved Horizon Therapeutics Ireland DAC’s teprotumumab-trbw (Tepezza) as the first FDA-approved treatment for adults with thyroid eye disease (TED). TED is a rare disorder which causes the...

Making diabetes education more effective

Is individual or group education most effective for patients with diabetes? A systematic review in the Journal of Nursing Scholarship indicates that each has a role. Individual education is most effective in reducing HbA1c, and...

FDA to host meeting on the development of products for rare diseases

On February 24, the U.S. Food and Drug Administration (FDA) is hosting a public meeting to celebrate FDA Rare Disease Day 2020 which will focus on what the future holds for the product development...

Study fails to show benefit of adding vitamin C to treatment of septic shock

A study recently published in the Journal of the American Medial Association aimed to examine if a treatment combination of vitamin C, hydrocortisone, and thiamine would lead to a “rapid resolution of septic shock”...

First targeted therapy for rare mutation of gastrointestinal stromal tumors

The U.S. Food and Drug Administration (FDA) recently announced the approval of Blueprint Medicines Corporation’s avapritinib (Ayvakit) for the treatment of adult patients with metastatic gastrointestinal stromal tumor (GIST) with the “platelet-derived growth factor...

First FDA-approved treatment for preventing Ebola virus

In late December 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Merck’s Ervebo, the first FDA-approved vaccine to prevent Ebola virus disease. The FDA Deputy Commissioner for Policy, Legislation, and International...

New guidelines for the management of school-based asthma

The Community Preventative Services Task Force (CPSTF) recently released new recommendations around the management of school-based asthma. These management strategies aim to reduce the amount of hospitalizations and emergency room visits from children and...

Potential consideration for physicians regarding cannabis edibles

In early January 2020, the Canadian Medical Association Journal published a commentary from Drs. Jasleen Grewal and Lawrence Loh regarding potential concerns around the use of cannabis edibles. One of the key points addressed in...

FDA issues warning letter for medication-assisted treatment for opioid use disorder

The U.S. Food and Drug Administration (FDA) recently issued a warning letter to Alkermes, Inc. due to misbranding on the drug Vivitrol, which is used to prevent opioid dependence relapse. The letter was issued...

Promoting safe use of parenteral anticoagulants

Nurses can take the lead in preventing harm related to heparin administration. Takeaways Parenteral anticoagulants require appropriate patient teaching to enhance adherence to medication administration. Use of unfractionated heparin/low-molecular weight heparins prevent adverse effects from...

10 years of inpatient diabetes certification— Lessons learned

Commitment and persistence pay off in improved outcomes. Takeaways Lessons learned and best practices from 10 years of Joint Commission inpatient diabetes certification. Changing inpatient culture and behaviors in diabetes care takes repeated data collection...

Potential new targeted therapy for Duchenne muscular dystrophy

The U.S. Food and Drug Administration (FDA) recently granted accelerated approval for Sarepta Therapeutics’ golodirsen (Vyondys 53), an injection for patients with Duchenne muscular dystrophy (DMD) with a mutation in the dystrophin gene “that...